Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Palvella Therapeutics, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palvella Therapeutics (PVLA) and Lifecore Biomedical...

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pfizer (PFE), Crispr Therapeutics AG (CRSP) and Palv...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Palvella Therapeutics, Inc. (($PVLA)) has held its Q2 earnings call. Read on for the main highlights of the call. Palvella Therapeutics’ latest ear...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PVLA	$149.97	-0.24%	191.99K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PVLA	$149.97	-0.2%	191.99K
3
4
5
6

PVLA

Get Palvella Therapeutics, Inc. Data in Excel

Get Palvella Therapeutics, Inc. Data in Excel